SG11201805139SA - Injectable composition and a method of treatment of the physical addiction - Google Patents

Injectable composition and a method of treatment of the physical addiction

Info

Publication number
SG11201805139SA
SG11201805139SA SG11201805139SA SG11201805139SA SG11201805139SA SG 11201805139S A SG11201805139S A SG 11201805139SA SG 11201805139S A SG11201805139S A SG 11201805139SA SG 11201805139S A SG11201805139S A SG 11201805139SA SG 11201805139S A SG11201805139S A SG 11201805139SA
Authority
SG
Singapore
Prior art keywords
international
composition
pct
total weight
treatment
Prior art date
Application number
SG11201805139SA
Inventor
Grace Consoni
Daryll Ian Knowles
Original Assignee
Verita Res Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905238A external-priority patent/AU2015905238A0/en
Application filed by Verita Res Pte Ltd filed Critical Verita Res Pte Ltd
Publication of SG11201805139SA publication Critical patent/SG11201805139SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 11111111011110111010101111101011111011101011101111111011011001111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/100863 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/485 (2006.01) A61K 47/34 (2017.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 9/08 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/AU2016/051255 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 16 December 2016 (16.12.2016) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 2015905238 17 December 2015 (17.12.2015) AU GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: VERITA RESEARCH PTE LTD [AU/AU]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Unit 2, 4 Endeavour Road, Caringbah, New South Wales DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 2229 (AU). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: CONSONI, Grace; Suite 1005, 275 Alfred SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Street, North Sydney, New South Wales 2060 (AU). GW, KM, ML, MR, NE, SN, TD, TG). KNOWLES, Daryll Ian; Suite 1005, 275 Alfred Street, Published: North Sydney, New South Wales 2060 (AU). — with international search report (Art. 21(3)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, 1-1 M GC © © 11 (54) Title: INJECTABLE COMPOSITION AND A METHOD OF TREATMENT OF THE PHYSICAL ADDICTION 1-1 C (57) : An injectable liquid composition for the treatment of a physical addiction includes naltrexone in the amount of 5%- el 95% of the total weight of the composition; at least two co-polymers in the amount of between 5% -95% of the total weight of the O composition; and a biocompatible water miscible organic solvent in the amount of 5% to 50% of the total weight of the composition. The composition is adapted to form a gel-like mass when contacted with an aqueous environment and to dissolve at a predetermined rate to release a therapeutic naltrexone dose over a predetermined period of time.
SG11201805139SA 2015-12-17 2016-12-16 Injectable composition and a method of treatment of the physical addiction SG11201805139SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015905238A AU2015905238A0 (en) 2015-12-17 Injectable Composition and a Method of Treatment of the Physical Addiction
PCT/AU2016/051255 WO2017100863A1 (en) 2015-12-17 2016-12-16 Injectable composition and a method of treatment of the physical addiction

Publications (1)

Publication Number Publication Date
SG11201805139SA true SG11201805139SA (en) 2018-07-30

Family

ID=59055408

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201805138VA SG11201805138VA (en) 2015-12-17 2016-12-16 Injectable composition and a method of treatment of the physical addiction
SG11201805139SA SG11201805139SA (en) 2015-12-17 2016-12-16 Injectable composition and a method of treatment of the physical addiction

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201805138VA SG11201805138VA (en) 2015-12-17 2016-12-16 Injectable composition and a method of treatment of the physical addiction

Country Status (6)

Country Link
US (1) US20190000834A1 (en)
CN (1) CN108601780A (en)
AU (1) AU2016374499A1 (en)
IL (1) IL260091A (en)
SG (2) SG11201805138VA (en)
WO (1) WO2017100863A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006036A (en) * 2018-12-27 2021-07-06 Alar Pharmaceuticals Inc Naltrexone injectable sustained release formulation.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
AU2001245346A1 (en) * 2000-06-28 2002-01-08 Atul J. Shukla Biodegradable vehicles and delivery systems of biologically active substances
CN1206001C (en) * 2000-06-28 2005-06-15 A·J·舒克拉 Biodegradable carrier and biodegradable transfer system
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions

Also Published As

Publication number Publication date
CN108601780A (en) 2018-09-28
WO2017100863A1 (en) 2017-06-22
AU2016374499A1 (en) 2018-08-02
SG11201805138VA (en) 2018-07-30
US20190000834A1 (en) 2019-01-03
IL260091A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
SG11201907034PA (en) Methods of treating influenza
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201804752TA (en) Device for reminding and measuring material level inside a material container
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201407988UA (en) Process for improved opioid synthesis
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201810786RA (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
SG11201804223TA (en) OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
SG11201804630SA (en) Preparation process for polypropylene with enhanced visual appearance
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201900043TA (en) Antibody formulations
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate
SG11201900214UA (en) Iso-citrate dehydrogenase (idh) inhibitor
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound
SG11201810123SA (en) Treatment of intrahepatic cholestatic diseases
SG11201909906QA (en) Organic compounds
SG11201809494VA (en) Pharmaceutical composition comprising eteplirsen
SG11201903064SA (en) Arsenic compositions